The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
about
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addictionNeurocomputational Nosology: Malfunctions of Models and MechanismsNew developments in the pharmacotherapy of cocaine abuseNonhuman primate neuroimaging and cocaine medication developmentActivation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortexCloning of the cocaine-sensitive bovine dopamine transporter.Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys.Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons.Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3Self-injurious behaviour in autistic children: a neuro-developmental theory of social and environmental isolation.Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands.2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations.Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic--A focus on analogues of benztropine and rimcazole.Intrinsic bioenergetic properties and stress sensitivity of dopaminergic synaptosomes.Differential effects of amphetamine and GBR-12909 on orolingual motor function in young vs aged F344/BN rats.Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma.Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan.Monoamine reuptake inhibitors in Parkinson's disease.Further structure-activity relationship studies on 8-substituted-3-[2-(diarylmethoxyethylidenyl)]-8-azabicyclo[3.2.1]octane derivatives at monoamine transporters.Effect of methylphenidate treatment during adolescence on norepinephrine transporter function in orbitofrontal cortex in a rat model of attention deficit hyperactivity disorder.Increased dopamine transporter function as a mechanism for dopamine hypoactivity in the adult infralimbic medial prefrontal cortex following adolescent social stressVoltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices.Brain dopamine and serotonin differ in regulation and its consequencesEvidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.Short-acting cocaine and long-acting GBR-12909 both elicit rapid dopamine uptake inhibition following intravenous delivery.Adolescence methylphenidate treatment in a rodent model of attention deficit/hyperactivity disorder: dopamine transporter function and cellular distribution in adulthood.Corticosterone acts in the nucleus accumbens to enhance dopamine signaling and potentiate reinstatement of cocaine seeking.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Hypothesis-driven medication discovery for the treatment of psychostimulant addictionVoltammetric detection of 5-hydroxytryptamine release in the rat brain.Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.The Discriminative Stimulus Properties of Drugs Used to Treat Depression and Anxiety.Methylphenidate facilitates learning-induced amygdala plasticityAge-related changes in prefrontal norepinephrine transporter density: The basis for improved cognitive flexibility after low doses of atomoxetine in adolescent rats.Low extracellular dopamine levels are maintained in the anoxic turtle (Trachemys scripta) striatum.Methylphenidate exerts dose-dependent effects on glutamate receptors and behaviors.Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.Food intake increases the relative oral bioavailability of vanoxerine.
P2860
Q24656085-A0E31F38-BF77-4B28-B934-EC3A2BA39FDEQ26747490-3AD79F5D-053B-454F-A23B-EC0FE62B8E6BQ28302782-AAF97EEE-101C-4DA6-9D8C-05D638261F23Q28304167-A56CF75D-6E5A-4790-A1C4-637F6774AB8AQ28574586-90FAC708-BEAC-4DEA-8CEB-D7CD640AC359Q33269223-29A38A3F-5999-464D-B1E8-018C12051022Q34105371-E1184A7A-D50D-4E54-A5A1-0D74B50E8144Q34359201-60BAC10D-AFEE-4B7F-A42E-7ED5A5DF8481Q34359911-14EDA8AB-DDB5-41EA-BC56-7781FBC98F2AQ34372746-0E3F57A7-902A-4005-914A-74DCD3254CC2Q34383909-4BF250F7-F97B-4A37-B164-B1ED53738E37Q34509115-EE0FDBA7-E72A-4302-8522-F8C367F4DCECQ34811630-E69B62AB-E853-43E9-B5EC-EA64A419D042Q34868333-2D97E547-8F1C-46D4-8AFE-C1A386E62C96Q34994144-F0C14D51-F928-4C5E-A148-9DF7DF1C41AEQ35037313-57DDEEA7-B417-47CA-9F04-E574585C97A0Q35108500-F0374E64-BDE9-452F-8C05-15C10494C209Q35165280-2FE70EAB-72B5-4259-885C-695072AB6CE0Q35590737-89D4F53A-E241-418A-8C8F-F457F0F21B00Q35908982-0675C314-2B7D-4A2A-9BEF-4A945AFDF686Q35956198-48A6F312-E5E1-44F7-A92F-CC66BD4CFBB9Q36092017-2625AE5E-35E4-404C-89ED-1574BC07BB52Q36122702-2D4820FD-2B80-49DD-997A-4D85232155EAQ36648476-7EF1AB2E-E2BB-4516-9F8F-E12FA799F7EEQ36882813-D8ED6790-40BC-4CD4-B8D5-F854C3C838B8Q37005445-5D7AC288-0693-4E81-9BFA-5834AEBE2DA9Q37020173-415A7558-0F79-4F6D-8A30-BF5FB794412BQ37158450-F2F944C8-C04C-4304-AA7E-A39F0811A58FQ37183687-34B4DD7C-22C8-43C0-8368-AF139CAFEC18Q37440730-D2D5A2BD-D972-4F20-9DA3-BE38FACE19DEQ37706110-D69C055F-35CF-45C3-A5F5-7B7FCB5A9503Q38187892-7051779F-60E4-49F7-B8B4-017045BA394AQ38837020-D6471029-67A7-4419-B5F7-2FE4B9A20782Q38847601-C9C65E1E-D0F7-40EC-A91D-7EA63518EC8CQ41707782-08007A58-7436-4933-A715-E71C9CEACC68Q41967394-3B3880D6-CEAC-4AE7-8BA4-2891F81221BCQ42458139-574D33F3-BF6E-4203-AED0-AC4FD9FA5495Q42548261-80D73719-6CDE-47C0-BF49-FC0B438B36A2Q43096386-D63F3B55-4BC0-4D97-9809-E15EB52A103BQ43224621-602FF92A-9696-4F00-8846-BFD40A3851BD
P2860
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
description
1989 nî lūn-bûn
@nan
1989 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@ast
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@en
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@nl
type
label
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@ast
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@en
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@nl
prefLabel
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@ast
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@en
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@nl
P1476
The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.
@en
P2093
Andersen PH
P304
P356
10.1016/0014-2999(89)90363-4
P407
P577
1989-08-01T00:00:00Z